Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025)
Keros Therapeutics (KROS) posted Cash from Investing Activities of -$134000.0 for Q4 2025, down 1.52% on a QoQ basis from -$132000.0 in Q3 2025, and up 53.63% year-over-year from -$87220.7 in Q4 2024.
Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Keros Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$134000.0 for Q4 2025.
- Quarterly Cash from Investing Activities rose 53.63% year-over-year to -$134000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 million (up 19.68% YoY) and the FY2025 annual result came in at -$1.6 million, up 19.68% from the prior year.
- Cash from Investing Activities was -$134000.0 for Q4 2025 at Keros Therapeutics, down from -$132000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$132000.0 in Q3 2025 and bottomed at -$1.1 million in Q1 2023.
- A 5-year average of -$410550.0 and a median of -$331000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 1721.43% — and 2025, when it surged 65.8%.
- Keros Therapeutics' Cash from Investing Activities stood at -$159000.0 in 2021, then slumped by 120.75% to -$351000.0 in 2022, then plunged by 54.13% to -$541000.0 in 2023, then jumped by 46.58% to -$289000.0 in 2024, then surged by 53.63% to -$134000.0 in 2025.
- Business Quant data shows KROS's Cash from Investing Activities at -$134000.0 in Q4 2025, -$132000.0 in Q3 2025, and -$720000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - | -134,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -134,000.00 |
| Dec 31, 2025 | -134,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Jun 30, 2025 | -720,000.00 |
| Jun 30, 2025 | -720,000.00 |
| Mar 31, 2025 | -565,000.00 |
| Mar 31, 2025 | -565,000.00 |
| Dec 31, 2024 | -289,000.00 |
| Dec 31, 2024 | -289,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Jun 30, 2024 | -310,000.00 |
| Jun 30, 2024 | -310,000.00 |
| Mar 31, 2024 | -946,000.00 |
| Mar 31, 2024 | -946,000.00 |
| Dec 31, 2023 | -541,000.00 |
| Dec 31, 2023 | -541,000.00 |
| Sep 30, 2023 | -550,000.00 |
| Sep 30, 2023 | -550,000.00 |